Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

TECHEU VD TENSIVE (BIOTECH ACT)

Summary sheet

Release date
1 April 2026
Reference
20260015
Project name
Promoter - financial intermediary
TECHEU VD TENSIVE (BIOTECH ACT)
TENSIVE SRL
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 20 million
EUR 44 million
Location
Sector(s)
Description
Objectives

The project concerns the promoter's research and development activities and CAPEX expenditures to advance regenerative implants for reconstructive surgery and for tissue marking following lumpectomy or mastectomy in breast cancer patients.

The project focuses on the development, clinical validation, and regulatory approval of REGENERA/SOFTAG, an innovative bioresorbable implant and precision tissue marker designed to support tissue regeneration following lumpectomy (i.e., partial breast removal after breast cancer). In parallel, the associated R&D investments also encompass clinical research into a novel post-mastectomy indication (i.e., full breast removal after breast cancer), leveraging advanced biomaterial 3D printing technology to enable the development of next-generation reconstructive implants.

Environmental aspects
Procurement

The project would not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC as research, development and innovation activities will be carried out in facilities already authorised for the same purpose. Full environmental details will nevertheless be verified to align with EU best practices.

The EIB requires that all project contracts are procured in accordance with the applicable EU procurement legislation.

Related projects
Parent project
TECHEU THEMATIC INNOVATION (INVESTEU VD) LE II

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications